ARCHIVES

Secondary AML In High-Dose Chemo Trial Cause For Careful Monitoring, NCI Says

This article is from The Cancer Letter archive.

Vol. 20 No. 33 | August 19, 1994

Download PDF Visit The Full Archive

Related Articles

Xeloda As Effective As 5-FU/LV, Five-Year Survival Data Show

September 28, 2007

BRAF Mutation Testing Classifies Indeterminate FNA Samples

March 29, 2013

Vanderbilt Recruits Sosman To Lead Tumor Immunology.

January 18, 2002

Skipper To Receive Bristol-Myers Award

March 14, 1980

NTP Bioassay Reports Will Include Other Tests In Assessing Potential Human Risk

January 23, 1981

In Brief: Frozen Panels Available to Evaluate diagnostic Assays; Panel to Meet at Johns Hopkins April 22

March 15, 1985